Low-dose radiation for early-stage mycosis fungoides
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a low-dose radiation treatment to the skin for early-stage mycosis fungoides, a type of lymphoma that affects the skin. The goal is to see if this treatment can help eliminate the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with stage IB or IIA mycosis fungoides.
- You are generally able to take care of yourself (WHO performance status score 2 or less).
- You are able to stand or maintain the required position during treatment.
- You have not had radiation therapy to the skin in the past that would limit this treatment.
- You have not had phototherapy in the past that would limit this treatment.
- You have no other skin cancers or conditions that would make phototherapy unsafe (like lupus, xeroderma pigmentosum, or porphyria).
- You are not pregnant or breastfeeding.
- You do not have severe liver, kidney, or heart problems that would prevent you from taking methoxsalen.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
This study tests a cream that targets inflammation in the skin for people with early-stage mycosis fungoides, a type of lymphoma. It may help relieve symptoms and slow the disease without stronger treatments.
This trial tests a spray solution applied to skin lesions caused by mycosis fungoides, a type of cutaneous T cell lymphoma. It aims to see how the spray affects bacteria on the skin and whether it helps the lesions.
Hear when a new Mycosis Fungoides trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.